![]() “The study adds to what we know,” said Dr. If sleep chronotype is affecting how our bodies use insulin and impacting metabolism, then being a night owl might be useful in predicting a person’s risk for heart disease and type 2 diabetes, Malin added. A drop of water isn’t going to make it soft again.” “But if you’re not exercising, engaging those muscles, it’s like if that sponge was to sit for a couple days and get rock hard. “Think about it like water from a water faucet: You turn the water on and a drop touches the sponge and is immediately absorbed,” Malin said. “Insulin tells the muscles to be a sponge and absorb the glucose in the blood,” said senior study author Steven Malin, an associate professor in the department of kinesiology and health at Rutgers University in New Jersey. Night owls were also more likely to be insulin-resistant, meaning their muscles required more insulin to be able to get the energy they need, according to the study published Monday in the journal Experimental Physiology. Night owls were more sedentary, had lower aerobic fitness levels and burned less fat at rest and while active than early birds in the study. Kristin Deuber, +1 614.975.4186, Benjafield AV et al.Are you a night owl or morning lark? One may protect you from depression, study says The transaction is not material to ResMed's consolidated financial results its financial terms were not disclosed. "It will take the combined efforts of sleep labs and connected home solutions like NightOwl to identify a significant portion of the hundreds of millions of people suffering from this disease that don't even know it."Įctosense will operate within ResMed's Sleep and Respiratory Care business. "ResMed has the global reach and passionate ambition to help increase patient access to Ectosense's proven diagnostic solution and a path to better sleep and overall health," said Frederik Massie, chief technology officer and cofounder of Ectosense. ![]() ![]() We're excited to welcome Ectosense's life-changing team to the ResMed family." "Ectosense's clinically validated, consumer-friendly devices will enable us to help millions of people in many markets improve their sleep and overall health. "In developing markets, we need to make sleep tests affordable, accessible and easy to use," said Justin Leong, ResMed president of Asia and Latin America. 2 Digital health solutions help patients stay on sleep apnea therapy once they start (up to 87% are adherent on connected solutions). For millions of people, their best night's sleep must start with a diagnosis."Īn estimated 936 million people worldwide have sleep apnea, 1 and over 80% remain undiagnosed. "We believe Ectosense's digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. ![]() "Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea," said Jim Hollingshead, ResMed president of Sleep and Respiratory Care. ResMed has distributed NightOwl in Australia, New Zealand, and India since 2020 under the brand "ResMed onesleeptest™," and has been a minority investor in Ectosense since July 2020. ![]() OctoResMed today has completed the acquisition of Ectosense, a leader in cloud-connected home sleep test (HST) devices that can help millions of people with undiagnosed sleep apnea get the treatment they need - and raise general awareness of the disease.Įctosense's FDA-approved NightOwl™ is sold in the United States, Australia, New Zealand, India, and parts of Europe. Ectosense's NightOwl™ is a leading FDA-approved cloud-connected home sleep apnea test ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |